526 related articles for article (PubMed ID: 34169635)
1. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
[TBL] [Abstract][Full Text] [Related]
2. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
[TBL] [Abstract][Full Text] [Related]
4. Cathelicidin-related antimicrobial peptide protects against cardiac fibrosis in diabetic mice heart by regulating endothelial-mesenchymal transition.
Zheng X; Peng M; Li Y; Wang X; Lu W; Wang X; Shan Y; Li R; Gao L; Qiu C
Int J Biol Sci; 2019; 15(11):2393-2407. PubMed ID: 31595157
[No Abstract] [Full Text] [Related]
5. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-
Liu L; Luo H; Liang Y; Tang J; Shu Y
Comput Math Methods Med; 2022; 2022():3293054. PubMed ID: 35096128
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
7. Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy.
Liu X; Mujahid H; Rong B; Lu QH; Zhang W; Li P; Li N; Liang ES; Wang Q; Tang DQ; Li NL; Ji XP; Chen YG; Zhao YX; Zhang MX
J Cell Mol Med; 2018 Feb; 22(2):808-822. PubMed ID: 29063670
[TBL] [Abstract][Full Text] [Related]
8. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
El-Shafey M; El-Agawy MSE; Eldosoky M; Ebrahim HA; Elsherbini DMA; El-Sherbiny M; Asseri SM; Elsherbiny NM
Front Endocrinol (Lausanne); 2022; 13():862394. PubMed ID: 35370937
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
Yang Z; Li T; Xian J; Chen J; Huang Y; Zhang Q; Lin X; Lu H; Lin Y
FASEB J; 2022 Jul; 36(7):e22410. PubMed ID: 35713937
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.
El-Sayed N; Mostafa YM; AboGresha NM; Ahmed AAM; Mahmoud IZ; El-Sayed NM
Chem Biol Interact; 2021 Sep; 347():109617. PubMed ID: 34391751
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
[TBL] [Abstract][Full Text] [Related]
13. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
Hodrea J; Saeed A; Molnar A; Fintha A; Barczi A; Wagner LJ; Szabo AJ; Fekete A; Balogh DB
PLoS One; 2022; 17(2):e0263285. PubMed ID: 35176041
[TBL] [Abstract][Full Text] [Related]
15. Reduced
Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus.
Belosludtsev KN; Starinets VS; Belosludtsev MN; Mikheeva IB; Dubinin MV; Belosludtseva NV
Mitochondrion; 2021 Jul; 59():246-254. PubMed ID: 34144205
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Shi L; Zhu D; Wang S; Jiang A; Li F
Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
[TBL] [Abstract][Full Text] [Related]
19. A novel role of kallikrein-related peptidase 8 in the pathogenesis of diabetic cardiac fibrosis.
Du JK; Yu Q; Liu YJ; Du SF; Huang LY; Xu DH; Ni X; Zhu XY
Theranostics; 2021; 11(9):4207-4231. PubMed ID: 33754057
[No Abstract] [Full Text] [Related]
20. Cell death-inducing DFFA-like effector C/CIDEC gene silencing alleviates diabetic cardiomyopathy via upregulating AMPKa phosphorylation.
Zhou HM; Ti Y; Wang H; Shang YY; Liu YP; Ni XN; Wang D; Wang ZH; Zhang W; Zhong M
FASEB J; 2021 May; 35(5):e21504. PubMed ID: 33913563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
